For information about COVID-19, including symptoms, prevention and travel advice, please read our COVID-19 patient guide, visit the NYC Department of Health or call our hotline: (646) 697-4000. If you have developed a fever, cough, shortness of breath or other respiratory symptoms, please call your provider before visiting one of our practice locations.
The Belfer Gene Therapy Core Facility (BGTCF) is a cutting-edge genetic medicine research facility that provides the capacity to:
- synthesize new gene therapy vectors based on adenovirus, adeno-associated virus, or lentivirus replication-deficient platforms
- validate the function of vectors
- perform pre-clinical testing in proof-of-concept models
- conduct toxicology, safety and distribution studies in support of regulatory filings
- produce GMP-grade vector for clinical trials.
BGTCF staff work closely with faculty in the Department of Genetic Medicine and other departments at Weill Cornell Medical College to support research in the area of gene therapy, as well as provide contract services to outside academic and corporate groups in need of the specific expertise and capabilities of the facility.
For more information, please contact the BGTCF directly:
Belfer Gene Therapy Core Facility
Stephen Kaminsky, PhD
Professor of Research in Genetic Medicine
Associate Director
515 E. 71st St. Suite S1000
New York, NY 10021
(212) 746-9952
smkamins@med.cornell.edu
